Does pulmonary fibrosis cause hyponatremia?

Does Pulmonary Fibrosis Cause Hyponatraemia?

Pulmonary fibrosis itself does not directly cause hyponatraemia, but pirfenidone—a medication used to treat idiopathic pulmonary fibrosis—can induce hyponatraemia through SIADH (syndrome of inappropriate antidiuretic hormone secretion).

Drug-Induced Hyponatraemia from Pirfenidone

The most clinically relevant connection between pulmonary fibrosis and hyponatraemia is medication-related, not disease-related. Pirfenidone, approved for treating idiopathic pulmonary fibrosis, causes hyponatraemia in approximately 3.4-5.8% of patients through SIADH 1. This represents a significant adverse effect that requires monitoring.

Key Clinical Points:

• Pirfenidone induces SIADH: Laboratory findings show euvolemic hypoosmolar hyponatraemia with inappropriately concentrated urine 1
• Incidence: 5.8% developed severe hyponatraemia in one retrospective analysis, compared to 0% in patients on nintedanib (the alternative antifibrotic agent) 1
• Management: Discontinuation of pirfenidone is typically required when severe hyponatraemia develops 1

Pulmonary Disease and Hyponatraemia: The Broader Context

While pulmonary fibrosis itself doesn't cause hyponatraemia, other pulmonary conditions can:

Lung Cancer and SIADH

Small cell lung cancer produces ADH in 10-45% of cases, though only 1-5% develop symptomatic SIADH 2. This is the classic paraneoplastic cause of hyponatraemia in pulmonary disease, but it's unrelated to fibrotic lung disease.

Pulmonary Infections

Pulmonary tuberculosis can cause hyponatraemia through SIADH, particularly in endemic regions 3. Pneumonia and bronchiolitis in children commonly present with hyponatraemia due to elevated ADH 4.

Clinical Algorithm for Evaluation

When encountering hyponatraemia in a patient with pulmonary fibrosis:

1. First, review medications: Check if the patient is taking pirfenidone—this is the most likely culprit
2. Assess volume status: Determine if euvolemic (SIADH), hypovolemic (volume depletion), or hypervolemic (heart failure)
3. Laboratory workup for SIADH 2:
   • Serum sodium <134 mEq/L
   • Plasma osmolality <275 mosm/kg
   • Urine osmolality >500 mosm/kg (inappropriately concentrated)
   • Urinary sodium >20-40 mEq/L
   • Exclude hypothyroidism, adrenal insufficiency, and volume depletion
4. Consider alternative diagnoses: Rule out heart failure (common comorbidity), lung malignancy, or pulmonary infection

Management Considerations

If pirfenidone-induced SIADH is confirmed:

• Discontinue pirfenidone 1
• Consider switching to nintedanib (no reported hyponatraemia risk) 1
• Implement standard SIADH management: fluid restriction <1 L/day for mild cases; hypertonic 3% saline for severe symptomatic cases (sodium <120 mEq/L) 2

Important caveat: The rate of sodium correction should not exceed 10 mmol/L per day to avoid osmotic demyelination syndrome 5. In severe symptomatic cases, an increase of ≤6 mmol/L per day is the therapeutic goal 4.

Common Pitfall to Avoid

Do not assume hyponatraemia in pulmonary fibrosis patients is due to the underlying lung disease itself. The fibrotic process does not produce ADH or cause electrolyte disturbances. Always investigate medication effects (especially pirfenidone), comorbid conditions (heart failure, malignancy), and alternative pulmonary pathology (infection, cancer) as the actual causes 1.